Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

PPARγ activity in cardiovascular diseases: a potential pharmacological target

Abstract :

Activation of peroxisome proliferator-activated receptors (PPARs), and particularly of PPARα and PPARγ, using selective agonists, is currently used in the treatment of metabolic diseases such as hypertriglyceridemia and type 2 diabetes mellitus. PPARα and PPARγ anti-inflammatory, antiproliferative and antiangiogenic properties in cardiovascular cells were extensively clarified in a variety of in vitro and in vivo models. In contrast, the role of PPARδ in cardiovascular system is poorly understood. Prostacyclin, the predominant prostanoid released by vascular cells, is a putative endogenous agonist for PPARδ, but only recently PPARδ selective synthetic agonists were found, improving studies about the physiological and pathophysiological roles of PPARδ activation. Recent reports suggest that the PPARδ activation may play a pivotal role to regulate inflammation, apoptosis, and cell proliferation, suggesting that this transcriptional factor could become an interesting pharmacological target to regulate cardiovascular cell apoptosis, proliferation, inflammation, and metabolism.

Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Okina Univ Angers Connectez-vous pour contacter le contributeur
Soumis le : jeudi 1 juillet 2021 - 14:07:34
Dernière modification le : dimanche 26 juin 2022 - 12:17:36

Lien texte intégral




Angela Tesse, Ramaroson Andriantsitohaina, Thierry Ragot. PPARγ activity in cardiovascular diseases: a potential pharmacological target. PPAR Research, Hindawi Publishing Corporation, 2009, 2009, pp.745 - 821. ⟨10.1155/2009/745821⟩. ⟨hal-03275805⟩



Consultations de la notice